Paul Gregor

Paul Gregor is an entrepreneur and investor with expertise in drug discovery, chemical biology, and human therapeutics. He received his Ph.D. from the Weizmann Institute of Science (Rehovot, Israel) and was a post-doctoral fellow at the National Institute on Drug Abuse, National Institutes of Health (NIDA/NIH, Baltimore, MD). For his post-doctoral work, Dr. Gregor received a NIDA Special Recognition Award. Dr. Gregor has co-authored seven patent families and published more than 30 manuscripts including articles in prestigious journals Nature and Science. Dr. Gregor’s industrial experience spans over 15 years in pharmaceutical and biotech companies, including as Research Scientist and Laboratory Head in metabolic disorders drug discovery at Bayer Pharmaceuticals Corp. (West Haven, CT), Head of R&D at Insight Biopharmaceuticals Ltd. (Israel).and founder and CEO of Rimonyx Pharmaceuticals Ltd. (Israel). Dr. Gregor founded Gismo Therapeutics Inc. based on his innovative drug discovery concept, Glycosaminoglycan-Interacting Small Molecule (GISMO) compounds. Dr. Gregor has an established track record in securing investments and grant awards and informing and managing industry and academia collaborations.